Novo drops oncology ambitions, early-stage MASH prospects in ongoing R&D shake-up
Novo Nordisk is winding down a range of early-stage programs for liver disease, oncology and stem cells as part of the Danish Pharma’s ambitious restructuring. This morning’s third-quarter earnings results…